Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy(Guangzhou Ruixin Biotechnological)

N/A

Report date: 2024/11/25 20:00:28

Base Information

Drug NameInduced Pluripotent Stem Cells Derived Natural Killer Cells Therapy(Guangzhou Ruixin Biotechnological)
Drug Alias NameiNK cells Therapy(Guangzhou Ruixin Biotechnological)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionStem cell replacementsNatural killer cell replacements
TargetsUpdating
Therapy Area/IndicationsSmall Cell Lung CarcinomaLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Ruixin Biotechnological Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Ruixin Biotechnological Co Ltd
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A